Nguyen Vu, Kanth Rajan, Gazo Joshua, Sorrentino Dario
a Gastroenterology , Virginia Tech - Carilion School of Medicine , Roanoke , VA , United States.
b Clinical and Experimental Medical Sciences , University of Udine Medical School , Udine , Italy.
Expert Rev Gastroenterol Hepatol. 2016 Nov;10(11):1257-1269. doi: 10.1080/17474124.2016.1241708. Epub 2016 Oct 7.
Postoperative recurrence (POR) of Crohn's disease is common after surgical resection. How to best manage POR remains uncertain. Areas covered: In this review, we will first describe the natural course and the best modalities to diagnose this surgical sequela. We will then focus on the potential risk factors for relapse and highlight the main shortcomings in the current study designs and endoscopic and clinical scoring systems, which may partly explain the unexpected outcomes of recent clinical trials. Finally, we will propose a strategy to address the management of POR. Expert commentary: Anti-tumor necrosis factor (Anti-TNF) agents are the most effective therapy to prevent POR in Crohn's disease. Patient risk stratification and active monitoring with scheduled ileocolonoscopy are cornerstones of optimal POR management. Further studies are needed to address areas of uncertainty including timing and duration of therapy and the role of therapeutic drug monitoring in this setting.
克罗恩病术后复发(POR)在手术切除后很常见。如何最佳管理POR仍不确定。涵盖领域:在本综述中,我们将首先描述这种手术后遗症的自然病程以及诊断的最佳方式。然后,我们将关注复发的潜在风险因素,并强调当前研究设计以及内镜和临床评分系统中的主要缺陷,这些缺陷可能部分解释了近期临床试验出人意料的结果。最后,我们将提出一种应对POR管理的策略。专家评论:抗肿瘤坏死因子(抗TNF)药物是预防克罗恩病POR最有效的疗法。患者风险分层以及定期进行回结肠镜检查的主动监测是优化POR管理的基石。需要进一步研究以解决包括治疗时机和持续时间以及治疗药物监测在此情况下的作用等不确定性领域。